Karen L Tubridy
CIK 1589888 · SVP, Chief Development Officer · last filed 2020-03-02
Karen L Tubridy is a SVP, Chief Development Officer who has filed 14 SEC Form 4 insider transactions across 2 companies since 2015. The most recent filing, for AKBA, was dated Mar 2, 2020. Across all open-market trades the lifetime net is −$51.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $36.0K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AKBA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
215 FIRST STREET, SUITE 400
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AKBA | SVP, Chief Development Officer | 84,679 | $0.42 | $36.0K | -$30.0K | 7 | 2020-03-02 |
| Carisma Therapeutics Inc. (EBIO) Delisted | Chief Development Officer | 32,753 | — | — | -$21.7K | 7 | 2016-07-12 |
Recent Filings
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-03-02 | AKBA | Mixed | +26,546 | -$30.0K | EDGAR |
| 2019-04-12 | AKBA | Disp (D) | −6,075 | -$46.8K | EDGAR |
| 2019-03-05 | AKBA | Grant (A) | +30,000 | $0 | EDGAR |
| 2018-12-13 | AKBA | Tax (F) | −11,928 | -$106.6K | EDGAR |
| 2018-03-02 | AKBA | Grant (A) | +17,500 | $0 | EDGAR |
| 2017-02-23 | AKBA | Grant (A) | +23,000 | $0 | EDGAR |
| 2016-12-02 | AKBA | Grant (A) | — | $0 | EDGAR |
| 2016-07-12 | Carisma Therapeutics Inc. (EBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-29 | Carisma Therapeutics Inc. (EBIO) Delisted | Sell (S) | −4,372 | -$9.1K | EDGAR |
| 2016-06-17 | Carisma Therapeutics Inc. (EBIO) Delisted | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).